Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | F10 | P00742 | 5/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5431955 | 0.92 | NPC1 (0.52) | NPC1RAB9AHPGDTSHRSMN1; SMN2 | |
| SCHEMBL5426602 | 0.92 | NPC1 (0.51) | NPC1RAB9AHPGDTSHRSMN1; SMN2 | |
| SCHEMBL4745381 | 0.84 | HPGD (0.54) | NPC1RAB9AHPGDTSHRSMN1; SMN2 | |
| SCHEMBL4746829 | 0.82 | F10 (0.66) | NPC1RAB9AHPGDTSHRSMN1; SMN2 | |
| SCHEMBL4747313 | 0.82 | RAB9A (0.65) | NPC1RAB9AHPGDTSHRSMN1; SMN2 | |
| SCHEMBL5443494 | 0.81 | NPC1 (0.55) | NPC1RAB9AHPGDTSHRSMN1; SMN2 | |
| SCHEMBL4744626 | 0.81 | RAB9A (0.67) | NPC1RAB9AHPGDTSHRSMN1; SMN2 | |
| SCHEMBL5435276 | 0.81 | F10 (0.64) | NPC1RAB9AHPGDTSHRSMN1; SMN2 | |
| SCHEMBL5442401 | 0.80 | HPGD (0.53) | NPC1RAB9AHPGDTSHRSMN1; SMN2 | |
| SCHEMBL5432420 | 0.79 | F10 (0.60) | F10F2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | QIAO JENNIFER X | 2007-06-14 | — | — | US | disclosed |
| US-7205318-B2 | Lactam-containing cyclic diamines and derivatives as a factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135428-A1 | LACTAM CONTAINING CYCLIC DIAMINES AND DERIVATIVES AS FACTOR XA INHIBITORS | F12, F2, PEPD | NPC1 4319/4885RAB9A 3566/4885HPGD 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.